Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
T. M. A. Abdel-Fatah(Nottingham University Hospitals NHS Trust), Stephen Chan(Heidelberg University), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Christina J. Perry(Florey Institute of Neuroscience and Mental Health), Ian O. Ellis(University of Nottingham), Graham Ball(Computer Algorithms for Medicine), P. Dickinson(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cited by 88
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k